¿Cuáles son las pautas para la insulinización y manejo de la insulina?

Respuesta generada por Itaca · 6 fuentes · 14 de abril de 2026

Pregunta original

1. Criterios de Insulinizacion. 2. Tipos de Insulina. 3. Esquemas de Insulina. 4. Como se inicia el tratamiento con Insulina y como se titula? 5. Como se avanza al siguiente esquema? 6. Efectos adversos de tratamiento con insulina. 7. Educacion al paciente: Traslado de farmacia al hogar. Tecnica de Administracion. Almacenamiento. Disposicion de desechos. Signos de hipoglucemia.

Summary
Below is a concise, clinically oriented overview of insulin initiation and management in type 2 diabetes, aligned with major guidelines (ADA, EASD, AACE). It covers criteria to start insulin, insulin types, regimens, initiation and titration, treatment progression, adverse effects, and key points for patient education.[1]``[2]


1. Criteria for Starting Insulin in Type 2 Diabetes

Insulin is indicated when any of the following apply:[1]``[2]

  1. Severe hyperglycemia at diagnosis or follow‑up

    • A1c ≥10% (≥86 mmol/mol) and/or
    • Fasting plasma glucose ≥250–300 mg/dL (≥13.9–16.7 mmol/L), or
    • Random glucose ≥300 mg/dL with symptoms (polyuria, polydipsia, weight loss, ketosis).[1]
  2. Symptomatic or catabolic state

    • Weight loss, ketosis, ketonuria, or hyperosmolar state.
    • Acute illness, surgery, myocardial infarction, stroke, pregnancy.
  3. Failure of oral/GLP‑1 therapy

    • A1c remains above individualized goal (commonly >7–8%) despite maximally tolerated oral agents and/or GLP‑1RA for 3–6 months.[1]``[2]
  4. Contraindications/intolerance to multiple non‑insulin agents

    • Advanced CKD or hepatic insufficiency limiting oral options.

Insulin can be temporary (e.g., during acute illness) or long‑term depending on response and underlying β‑cell reserve.[1]


2. Types of Insulin (Clinical Classification)

A. Basal (Long‑acting) Insulin

Provides relatively constant background insulin:

  • NPH (isophane) – intermediate‑acting (peak ~4–8 h, duration ~12–18 h).
  • Long‑acting analogs:
    • Glargine (U100, U300),
    • Detemir,
    • Degludec (ultra‑long).

Clinical notes:

  • Long‑acting analogs have flatter profiles and less nocturnal hypoglycemia than NPH.[3]``[4]
  • Degludec and glargine U300 allow more flexible dosing time.[3]

B. Prandial (Rapid‑acting) Insulin

Covers meal‑related glucose rises:

  • Rapid‑acting analogs: lispro, aspart, glulisine; onset ~10–20 min, peak ~1–3 h, duration 3–5 h.[3]
  • Ultra‑rapid analog formulations (e.g., faster‑acting aspart) with slightly faster onset.

C. Premixed Insulins

Fixed combinations of basal (NPH or analog) + prandial component:

  • Human premix (e.g., 70/30 NPH/regular).
  • Analog premix (e.g., 70/30 or 75/25 NPH‑analog mix).

Useful when:

  • Regular meal pattern.
  • Simpler regimen is needed and full basal‑bolus is not feasible.[1]

D. Concentrated Insulins

Same type but higher concentration (e.g., U200, U300, U500) used for insulin‑resistant patients needing high doses. Require careful patient education.


3. Common Insulin Regimens (“Esquemas”)

3.1 Basal‑Only Regimen

  • Once‑daily basal insulin (evening or morning).
  • Typically combined with oral agents ± GLP‑1RA.[1]``[2]
  • First‑line insulin approach in most T2D patients.

3.2 Basal‑Plus (Basal

  • 1 Mealtime Dose)
  • Basal insulin + one prandial dose at the largest meal or the meal with greatest postprandial excursion.
  • Step between basal‑only and full basal‑bolus.[2]

3.3 Basal‑Bolus (Multiple Daily Injections)

  • Basal insulin once daily + rapid‑acting insulin before each main meal (typically 3 times/day).
  • Offers greatest flexibility and best mimicry of physiologic insulin but requires more injections and monitoring.[1]

3.4 Premixed Regimen

  • Twice‑daily premixed insulin (before breakfast and dinner).
  • Sometimes 3‑times daily in selected cases.
  • Less flexible than basal‑bolus; risk of hypoglycemia if meals skipped or delayed.

Choice depends on:

  • A1c pattern (fasting vs postprandial elevation).
  • Meal schedule.
  • Patient ability for SMBG and carb counting.
  • Cost and access.[1]``[2]

4. How to Start Insulin and How to Titrate

4.1 Start Basal Insulin (Most Common in T2D)

Guideline‑based options (reasonably equivalent):[1]``[2]

  • Fixed dose: 10 units once daily.
  • Weight‑based: 0.1–0.2 units/kg/day (higher if A1c markedly elevated, e.g., 0.2–0.3 U/kg).

Continue metformin; consider keeping SGLT2i and/or GLP‑1RA if tolerable, and usually stop or reduce secretagogues (sulfonylureas) to reduce hypoglycemia risk.[1]

Basal Titration

  • Aim for fasting plasma glucose (FPG) ~80–130 mg/dL (4.4–7.2 mmol/L), individualized.[1]
  • Typical titration:
    • Increase by 2 units every 3 days if FPG > goal.
    • Or 10–15% of total daily dose every 3–7 days.
  • If FPG <70 mg/dL (3.9 mmol/L) or symptomatic hypoglycemia:
    • Reduce basal dose by 10–20% and reassess SMBG, diet, and other drugs.[1]

Use structured self‑monitoring (e.g., FPG daily or several times/week).

4.2 Initiate Prandial Insulin (Basal‑Plus)

Add rapid‑acting insulin before the largest meal when:

  • A1c remains above goal despite FPG at target (suggesting postprandial hyperglycemia).[1]``[2]

Starting dose:

  • 4 units, or
  • 0.1 U/kg, or
  • 10% of basal dose, before the largest meal.[1]

Titration:

  • Adjust by 1–2 units (or ~10–15%) twice weekly based on 2‑hour postprandial or next premeal glucose, aiming for ~100–180 mg/dL (5.6–10 mmol/L), individualized.[1]

4.3 Initiate Basal‑Bolus

Indicated when:

  • A1c remains above target despite optimized basal‑plus OR
  • Very high A1c and symptomatic hyperglycemia at presentation (catabolic state).[1]``[2]

Common approach:

  • Total daily dose (TDD): 0.3–0.5 U/kg/day (lower in older/frail, higher if very obese or on steroids).
  • Split: ~50% basal, 50% prandial divided across meals.
  • Titrate basal to FPG target and each bolus according to pre‑ and post‑meal glucose.

5. How to Progress to the Next Regimen

Use a stepwise approach guided by residual hyperglycemia pattern.[1]``[2]

  1. From oral agents → Basal insulin

    • If FPG elevated and A1c high despite oral therapy.
  2. From basal‑only → Basal‑plus or Premix
    Consider stepping up when:

    • Basal dose >0.5 U/kg/day and FPG at goal, but A1c still above target.
    • CGM/SMBG shows normal fasting but high postprandials.
      Options:
    • Convert to basal‑plus (add 1 mealtime injection) or
    • Switch to premixed insulin twice daily if simpler regimen needed.[1]
  3. From basal‑plus → Full basal‑bolus

    • Add prandial insulin to second then third main meal if A1c still not at goal.
  4. From premix → Basal‑bolus

    • If control inadequate and patient can manage more injections and monitoring.

At each step, reassess hypoglycemia risk, adherence, injection technique, diet, and comorbidities before simply increasing dose.[1]


6. Adverse Effects of Insulin Therapy

6.1 Hypoglycemia

  • Most important and common adverse effect.
  • Symptoms: sweating, tremor, palpitations, hunger, anxiety, confusion, visual changes; in severe cases seizures, loss of consciousness.
  • Risk factors: excess dose, missed/delayed meals, exercise without adjustment, renal insufficiency, alcohol, older age, use with sulfonylureas.[1]``[3]

Long‑acting analog basal insulins are associated with less nocturnal and overall hypoglycemia vs NPH in RCTs.[3]``[4]

6.2 Weight Gain

  • Insulin has anabolic effects and reduces glucosuria, typically causing weight gain of several kg over months.
  • Mitigation: dietary counseling, physical activity, combining with agents associated with weight neutrality or loss (metformin, SGLT2i, GLP‑1RA).[1]``[2]``[5]

6.3 Injection‑Site Issues

  • Pain, bruising, lipohypertrophy or lipoatrophy (if sites not rotated).
  • Rare allergic reactions or local infection.

6.4 Other

  • Edema (usually mild, transient).
  • Hypokalemia in overdose or in specific contexts (e.g., combined with high‑dose β‑agonists or in DKA treatment).

7. Patient Education (Key Points)

Education is essential for safety and effectiveness.[1]``[2]``[6]

7.1 From Pharmacy to Home (Transport)

  • Keep insulin between ~2–8 °C (refrigerated) before first use.
  • During transport:
    • Avoid freezing and excessive heat (>30 °C).
    • Use insulated bag or cool pack if travel is long or weather hot (ensure insulin is not directly touching ice).

7.2 Storage at Home

  • Unopened vials/pens: in refrigerator (2–8 °C), not in freezer.
  • In‑use vial/pen:
    • Most products can be kept at room temperature (up to ~25–30 °C, per specific product insert) for typically 28 days (some longer); label and follow product‑specific instructions.[6]
    • Protect from direct sunlight and heat.
  • Discard insulin that:
    • Has been frozen,
    • Looks cloudy or has particles (for clear insulins),
    • Is past expiration or beyond recommended in‑use period.

7.3 Injection Technique

Key teaching points:

  1. Preparation

    • Wash hands.
    • Check insulin type, dose, and expiration.
    • For NPH or premix: gently roll/tilt pen or vial to resuspend (do not shake vigorously).
  2. Site Selection

    • Preferred: abdomen (avoiding 2‑inch circle around navel), outer thigh, upper buttocks, posterior upper arm.
    • Rotate within and between sites to avoid lipohypertrophy.
  3. Technique

    • Use appropriate needle length (usually 4–6 mm for pens in adults).
    • Pinch skin if very lean; insert needle at 90° (or 45° for longer needles or very thin patients).
    • Inject slowly; count 10 seconds before removing pen needle to ensure full dose.
  4. Frequency of Changing Needles

    • Use a new needle for each injection to reduce pain, clogging, and lipohypertrophy.

Provide demonstration and return‑demonstration; written/visual materials help reinforce learning.[6]

7.4 Disposal of Sharps and Waste

  • Do not discard needles in regular household trash.
  • Place used needles and lancets in puncture‑resistant container (e.g., FDA‑cleared sharps container or heavy plastic bottle with secure lid).
  • Follow local regulations for sharps disposal (pharmacy/clinic drop‑off, community sharps program, etc.).

7.5 Recognition and Management of Hypoglycemia

Teach patients and family:

Typical symptoms

  • Autonomic: sweating, tremor, palpitations, hunger, anxiety.
  • Neuroglycopenic: confusion, difficulty speaking, blurred vision, drowsiness, behavior changes.

“15‑15 Rule” for Mild–Moderate Hypoglycemia

  • If blood glucose <70 mg/dL (3.9 mmol/L) and patient is awake and able to swallow:
    • Take 15 g of fast‑acting carbohydrate (e.g., 3–4 glucose tablets, 120–150 mL regular soda or juice).
    • Re‑check glucose in 15 minutes.
    • If still <70 mg/dL, repeat.
    • Once >70 mg/dL and next meal is >1 hour away, take longer‑acting carbohydrate (e.g., snack with starch + protein).

Severe Hypoglycemia (not fully conscious or cannot swallow)

  • Caregivers should be trained to:
    • Use glucagon (injection or nasal) if available.
    • Call emergency services.
  • After any severe episode, dose adjustment and regimen review are required.[1]

If you share a specific patient profile (age, comorbidities, A1c, current therapy, renal function), I can outline a tailored algorithm: when to start insulin, which regimen to choose first, and how to titrate safely in that context.


[1] American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. [1]
[2] Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022 consensus report by the ADA and EASD. Diabetologia. [2]
[3] Rosenstock J, et al. Reduced hypoglycemia with insulin glargine vs NPH in type 2 diabetes. Arch Intern Med. [3]
[4] Marso SP, et al. Degludec vs Glargine in type 2 diabetes (DEVOTE). N Engl J Med. [4]
[5] Nauck MA, et al. Weight considerations in type 2 diabetes management. Lancet. [5]
[6] Heinemann L, et al. Insulin injection technique: recommendations. Mayo Clin Proc. [6]

Fuentes

  1. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153308
  2. https://link.springer.com/article/10.1007/s00125-022-05787-2
  3. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/217514
  4. https://www.nejm.org/doi/full/10.1056/NEJMoa1615692
  5. https://www.sciencedirect.com/science/article/pii/S0140673613618885
  6. https://www.mayoclinicproceedings.org/article/S0025-6196(16)30344-3/fulltext

Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.

¿Tienes una pregunta sobre tu propio caso? Itaca responde con fuentes en segundos.

Hacer una pregunta

Más preguntas sobre diabetes mellitus